LONZA GROUP AG-REG (LO3.DE) Stock Price, Forecast & Analysis
Europe - FRA:LO3 - CH0013841017 - Common Stock
LO3.DE Key Statistics, Chart & Performance
The current stock price of LO3.DE is 598.6 EUR. In the past month the price increased by 3.89%.
LO3.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TN8.DE | THERMO FISHER SCIENTIFIC INC | 25.24 | 184.80B | ||
| DAP.DE | DANAHER CORP | 28 | 133.74B | ||
| QTS.DE | IQVIA HOLDINGS INC | 18.61 | 31.86B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 47.96 | 20.12B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 48.07 | 20.17B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 51.82 | 17.69B | ||
| ILU.DE | ILLUMINA INC | 28.05 | 16.25B | ||
| SRT.DE | SARTORIUS AG | 41.6 | 14.20B | ||
| ERF.PA | EUROFINS SCIENTIFIC | 16.98 | 11.13B | ||
| ESF0.DE | EUROFINS SCIENTIFIC | 16.96 | 11.12B | ||
| QIA.DE | QIAGEN N.V. | 19.84 | 8.73B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 19.93 | 2.91B |
Related stock screener links
About LO3.DE
Company Profile
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Company Info
LONZA GROUP AG-REG
Muenchensteinerstrasse 38
Basel BASEL-STADT CH
Employees: 19299
Phone: 41613168111
LONZA GROUP AG-REG / LO3.DE FAQ
What does LO3 do?
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
What is the stock price of LONZA GROUP AG-REG today?
The current stock price of LO3.DE is 598.6 EUR. The price decreased by -0.6% in the last trading session.
Does LO3 stock pay dividends?
LONZA GROUP AG-REG (LO3.DE) has a dividend yield of 0.72%. The yearly dividend amount is currently 4.3.
What is the ChartMill rating of LONZA GROUP AG-REG stock?
LO3.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of LO3 stock?
LONZA GROUP AG-REG (LO3.DE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the market capitalization of LO3 stock?
LONZA GROUP AG-REG (LO3.DE) has a market capitalization of 42.04B EUR. This makes LO3.DE a Large Cap stock.
LO3.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LO3.DE.
LO3.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to LO3.DE. Both the profitability and the financial health of LO3.DE get a neutral evaluation. Nothing too spectacular is happening here.
LO3.DE Financial Highlights
Over the last trailing twelve months LO3.DE reported a non-GAAP Earnings per Share(EPS) of 16.69. The EPS increased by 16.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.33% | ||
| ROA | 4.1% | ||
| ROE | 7.84% | ||
| Debt/Equity | 0.39 |
LO3.DE Forecast & Estimates
30 analysts have analysed LO3.DE and the average price target is 741.27 EUR. This implies a price increase of 23.83% is expected in the next year compared to the current price of 598.6.
For the next year, analysts expect an EPS growth of 11.86% and a revenue growth 14.55% for LO3.DE